Limits...
Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.

Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B - Med. Sci. Monit. (2011)

Bottom Line: The aim of this study was to examine the effect of octreotide on the survival of patients with advanced HCC.Whereas, when including the studies using placebo as control or being performed in western countries, the difference was not significant.The role of detecting SSTR expression in the administration of octreotide in advanced HCC needs further investigation.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, The Military General Hospital of Beijing PLA, Beijing, China.

ABSTRACT

Background: The role of somatostatin analogues in advanced hepatocellular carcinoma (HCC) remains controversial. The aim of this study was to examine the effect of octreotide on the survival of patients with advanced HCC.

Material/methods: Electronic databases including Medline, Embase, Cochrane controlled trials register, Web of Science and PubMed (updated to Dec 2010) and manual bibliographical searches were conducted. A meta-analysis of all randomized controlled trials (RCTs) comparing octreotide versus placebo or no treatment was performed.

Results: Eleven RCTs including 802 patients were assessed and 9 were included in the meta-analysis. Meta-analysis showed that the 6-mo and 12-mo survival rates in the octreotide group were significantly higher than those of the control group (6-mo: RR 1.41, 95%CI 1.12-1.77, P=0.003; 12-mo: RR 2.66, 95%CI 1.30-5.44, P=0.008). When including the studies using no treatment as control, with high quality, being performed in China, including >50 patients and with follow-up >2 years, the sensitivity analyses tended to confirm the primary meta-analysis. Whereas, when including the studies using placebo as control or being performed in western countries, the difference was not significant.

Conclusions: This meta-analysis demonstrates that octreotide could improve the survival of patients with advanced HCC, but possibly not in western countries. The role of detecting SSTR expression in the administration of octreotide in advanced HCC needs further investigation.

Show MeSH

Related in: MedlinePlus

Funnel plots of the included trials.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3539608&req=5

f3-medscimonit-17-8-ra169: Funnel plots of the included trials.

Mentions: Meta-analysis showed that the 6-mo and 12-mo survival rates in the octreotide group were significantly higher than those of the control group (6-mo: 53.89% vs. 41.45%, RR 1.41, 95%CI 1.12–1.77, P=0.003; 12-mo: 28.95% vs. 17.88%, RR 2.66, 95%CI 1.30–5.44, P=0.008) (Figure 2). The 24-mo survival rate was not different between the 2 groups (RR 1.08, 95%CI 0.40–2.94, P=0.88) (Figure 2). The funnel plots for the results showed obvious asymmetry, suggesting the possibility of bias (Figure 3).


Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.

Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B - Med. Sci. Monit. (2011)

Funnel plots of the included trials.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3539608&req=5

f3-medscimonit-17-8-ra169: Funnel plots of the included trials.
Mentions: Meta-analysis showed that the 6-mo and 12-mo survival rates in the octreotide group were significantly higher than those of the control group (6-mo: 53.89% vs. 41.45%, RR 1.41, 95%CI 1.12–1.77, P=0.003; 12-mo: 28.95% vs. 17.88%, RR 2.66, 95%CI 1.30–5.44, P=0.008) (Figure 2). The 24-mo survival rate was not different between the 2 groups (RR 1.08, 95%CI 0.40–2.94, P=0.88) (Figure 2). The funnel plots for the results showed obvious asymmetry, suggesting the possibility of bias (Figure 3).

Bottom Line: The aim of this study was to examine the effect of octreotide on the survival of patients with advanced HCC.Whereas, when including the studies using placebo as control or being performed in western countries, the difference was not significant.The role of detecting SSTR expression in the administration of octreotide in advanced HCC needs further investigation.

View Article: PubMed Central - PubMed

Affiliation: Department of General Surgery, The Military General Hospital of Beijing PLA, Beijing, China.

ABSTRACT

Background: The role of somatostatin analogues in advanced hepatocellular carcinoma (HCC) remains controversial. The aim of this study was to examine the effect of octreotide on the survival of patients with advanced HCC.

Material/methods: Electronic databases including Medline, Embase, Cochrane controlled trials register, Web of Science and PubMed (updated to Dec 2010) and manual bibliographical searches were conducted. A meta-analysis of all randomized controlled trials (RCTs) comparing octreotide versus placebo or no treatment was performed.

Results: Eleven RCTs including 802 patients were assessed and 9 were included in the meta-analysis. Meta-analysis showed that the 6-mo and 12-mo survival rates in the octreotide group were significantly higher than those of the control group (6-mo: RR 1.41, 95%CI 1.12-1.77, P=0.003; 12-mo: RR 2.66, 95%CI 1.30-5.44, P=0.008). When including the studies using no treatment as control, with high quality, being performed in China, including >50 patients and with follow-up >2 years, the sensitivity analyses tended to confirm the primary meta-analysis. Whereas, when including the studies using placebo as control or being performed in western countries, the difference was not significant.

Conclusions: This meta-analysis demonstrates that octreotide could improve the survival of patients with advanced HCC, but possibly not in western countries. The role of detecting SSTR expression in the administration of octreotide in advanced HCC needs further investigation.

Show MeSH
Related in: MedlinePlus